Content about Nephrology

December 23, 2010

The Food and Drug Administration on Wednesday approved Novartis Pharmaceuticals’ Amturnide (aliskiren, amlodipine and hydrochlorothiazide) tablets for the treatment of high blood pressure, according to the pharma company.

EAST HANOVER, N.J. — The Food and Drug Administration on Wednesday approved Novartis Pharmaceuticals’ Amturnide (aliskiren, amlodipine and hydrochlorothiazide) tablets for the treatment of high blood pressure, according to the pharma company. 

Amturnide combines the only approved direct rennin inhibitor worldwide, Tekturna (aliskiren), with the widely used calcium channel blocker amlodipine and the diuretic hydrochlorothiazide (HCTZ).

December 1, 2010

Drug maker Keryx Biopharmaceuticals got promising results from a late-stage clinical trial of a drug for treating elevated phosphate levels, also known as hyperphosphatemia, in patients on kidney dialysis, the company said Tuesday.

NEW YORK — Drug maker Keryx Biopharmaceuticals got promising results from a late-stage clinical trial of a drug for treating elevated phosphate levels, also known as hyperphosphatemia, in patients on kidney dialysis, the company said Tuesday.

In a phase-3 trial, Zerenex (ferric citrate) significantly reduced phosphate levels in patients with end-stage kidney disease on dialysis.

November 21, 2010

A cholesterol-lowering drug made by Merck appears to reduce the risk of heart attacks, strokes...

DENVER A cholesterol-lowering drug made by Merck appears to reduce the risk of heart attacks, strokes and cardiac death in patients with chronic kidney disease, according to results of a new study.

 

Merck said results of a 9,000-patient clinical study showed that Vytorin (ezetimibe and simvastatin) reduced the risks by 16.1% compared with placebo. Results of the study were presented Saturday at the annual meeting of the American Society of Nephrology.

 

 

October 25, 2010

Drug maker Keryx Biopharmaceuticals has finished enrolling participants for a late-stage clinical trial of a...

NEW YORK Drug maker Keryx Biopharmaceuticals has finished enrolling participants for a late-stage clinical trial of a drug for patients on kidney dialysis, Keryx said Tuesday.

 

The company is conducting a phase-3 trial of Zerenex (ferric citrate) in patients with end-stage kidney disease on dialysis who have excessive phosphorous levels, a condition known as hyperphosphatemia.

 

 

Keryx said it expects to complete the study and report top-line data by the end of the year.

 

September 28, 2010

Keryx has begun its phase-3 clinicial trial of a drug designed to treat elevated serum...

NEW YORK Keryx has begun its phase-3 clinicial trial of a drug designed to treat elevated serum phosphorous levels in patients with end-stage renal disease on dialysis.

September 22, 2010

Drug makers Abbott and Reata Pharmaceuticals have signed an agreement concerning a drug for chronic...

ABBOTT PARK, Ill. Drug makers Abbott and Reata Pharmaceuticals have signed an agreement concerning a drug for chronic kidney disease.

 

The two companies said Thursday that they would develop and commercialize bardoxolone methyl, currently in mid-stage clinical trials.

 

 

August 5, 2010

Drug maker Mission Pharmacal has launched a treatment for urinary tract infections....

SAN ANTONIO Drug maker Mission Pharmacal has launched a treatment for urinary tract infections.

 

Mission announced the launch of Uribel (methenamine, sodium phosphate monobasic, phenyl salicylate, methylene blue and hyoscyamine sulfave) capsules, used to relieve local discomfort and inflammation associated with lower urinary tract infections, interstitial cystitis, painful bladder syndrome and urinary tract procedures.

 

 

July 12, 2010

Generic drug maker Watson Pharmaceuticals hopes to be the first to market a version of...

MORRISTOWN, N.J. Generic drug maker Watson Pharmaceuticals hopes to be the first to market a version of a kidney disease treatment made by Genzyme, Watson said Monday.

Watson said it filed a regulatory approval application with the Food and Drug Administration for sevelamer carbonate for oral suspension. The drug is a generic version of Genzyme’s Renvela, used to control serum phosphorus in patients with chronic kidney disease who are on dialysis.

 

July 5, 2010

Generic drug maker Impax Labs is challenging the patent on a drug used to treat...

June 30, 2010

Lake Consumer Products on Wednesday announced its purchase of Consumer Choice Systems. The acquisition adds...

June 28, 2010

A recent study being published in the journal Urology found that Proantinox, a proprietary cranberry-based...

May 5, 2010

A Forest Labs drug used to treat mild to moderate hypertension “significantly” reduced blood pressure...

May 5, 2010

Keryx Biopharmaceuticals has started a late-stage clinical trial of a drug for patients on kidney...

February 1, 2010

Tiny areas of brain damage caused by injury to small blood vessels can signal an...